The American Association for Cancer Research (AACR) today announced its newly elected class of Fellows of the AACR Academy. Gordon J. Freeman, PhD, researcher at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School is included in the prestigious group of newly elected Fellows.
In making the announcement, AACR noted he was elected for groundbreaking contributions to the discovery of the PD-1 signaling pathway and the PD-1 ligands, PD-L1 and PD-L2, and for spotlighting the involvement of this pathway in tumor evasion of immunosurveillance.
The mission of the AACR Academy is to recognize and honor distinguished scientists whose scientific contributions have propelled significant innovation and progress against cancer. The Fellows of the AACR Academy serve as a global brain trust, helping to advance the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.
Consideration for election and induction into the AACR Academy is restricted to individuals whose work has had a significant and enduring impact on the cancer research field.
The 2019 class of elected Fellows encompasses 22 giants in the field of cancer research, and we are thrilled to have them join the ranks of the prestigious AACR Academy. Through groundbreaking work across the entire cancer continuum, these individuals have contributed immensely to the understanding, prevention, diagnosis, and treatment of cancer,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “We look forward to their induction and to celebrating their enduring global impact on cancer research.”
The AACR will formally induct its 2019 class of elected Fellows of the AACR Academy at the AACR Annual Meeting 2019, to be held in Atlanta, March 29-April 3.
For information on all members of the newly elected 2019 class of Fellows of the AACR Academy, visit: the AACR newsroom.